A phase I, randomized, double‐blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF‐06763809 in participants with mild‐to‐moderate plaque psoriasis

BACKGROUND: Transcription factor retinoic acid‐related orphan receptor 2 (RORC2/RORγT) mediates interleukin (IL)‐17A and IL‐17F expression. IL‐17A plays a central role in the pathogenesis of several inflammatory disorders, including psoriasis. The RORC2 inhibitor PF‐06763809 has been hypothesized to...

Descripción completa

Detalles Bibliográficos
Autores principales: Berstein, G., Zhang, Y., Berger, Z., Kieras, E., Li, G., Samuel, A., Yeoh, T., Dowty, H., Beaumont, K., Wigger‐Alberti, W., von Mackensen, Y., Kroencke, U., Hamscho, R., Garcet, S., Krueger, J. G., Banfield, C., Oemar, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756278/
https://www.ncbi.nlm.nih.gov/pubmed/32767679
http://dx.doi.org/10.1111/ced.14412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756278/
https://www.ncbi.nlm.nih.gov/pubmed/32767679
http://dx.doi.org/10.1111/ced.14412

Ejemplares similares